Effect of highly purified porcine gut glucagon-like immunoreactivity (glicentin) on glucose release from isolated rat hepatocytes

Thieden, H. I. D.; Holst, Jens J.; Dich, John; Moody, A. J.; Sundby, F.

doi:10.1016/0304-4165(81)90222-1

Cited by 18 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A first study found that glicentin stimulated the release of glucose from rat hepatocytes, with a stimulation of cAMP production, an effect comparable to what observed after incubation with glucagon ( 35 ). The authors observed that during incubation with hepatocytes glicentin was degraded into low molecular weight fragments, some being very similar to glucagon, addressing the question whether glicentin could exert glucagon-like effects through a possible degradation to glucagon.…”

Section: Glicentin and Glucose Metabolismmentioning

confidence: 66%

Insights on glicentin, a promising peptide of the proglucagon family

Raffort

Lareyre²,

Massalou³

et al. 2017

Biochemia Medica

View full text Add to dashboard Cite

Glicentin is a proglucagon-derived peptide mainly produced in the L-intestinal cells. While the roles of other members of the proglucagon family including glucagon-like peptide 1, glucagon-like peptide 2 and oxyntomodulin has been well studied, the functions and variation of glicentin in human are not fully understood. Experimental and clinical studies have highlighted its role in both intestinal physiology and glucose metabolism, pointing to its potential interest in a wide range of pathological states including gastrointestinal and metabolic disorders. Due to its structure presenting many similarities with the other proglucagon-derived peptides, its measurement is technically challenging. The recent commercialization of specific detection methods has offered new opportunities to go further in the understanding of glicentin physiology. Here we summarize the current knowledge on glicentin biogenesis and physiological roles. In the limelight of clinical studies investigating glicentin variation in human, we discuss future directions for potential applications in clinical practice.

show abstract

Section: Glicentin and Glucose Metabolismmentioning

confidence: 66%

Insights on glicentin, a promising peptide of the proglucagon family

Raffort

Lareyre²,

Massalou³

et al. 2017

Biochemia Medica

View full text Add to dashboard Cite

show abstract

“…The linearity of the dose/response curves was obtained with four doses for GLIC or OXM(19-37) and with three doses for OXM or OXM (30)(31)(32)(33)(34)(35)(36)(37). The analysis of covariance, performed on data from the linear part of the curves, indicated parallel slopes.…”

Section: Discussionmentioning

confidence: 99%

“…OXM [3,4], but not GLIC [35], has some glucagonlike effects on the liver via glucagon receptors. Moreover, OXM mimics the effect that glucagon activity has on glucose-induced insulin release [3,18,29].…”

Section: Introductionmentioning

confidence: 93%

“…OXM (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37) and OXM (30)(31)(32)(33)(34)(35)(36)(37) were synthesized in our laboratory by the solid-phase method using chloromethylated resin and the Boc-HF strategy. The coupling reactions were carried out manually with the use of benzotriazolyl-oxy tris dimethyl aminophosphonium hexafluorophosphate (BOP) [22].…”

Section: Peptidesmentioning

confidence: 99%

“…This work has demonstrated a specific myogenic effect of these hormones. The structure-activity relationship was investigated using GLIC, OXM and the two Cterminal fragments, OXM (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37) and OXM(30-37).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of glicentin, oxyntomodulin and related peptides on isolated gastric smooth muscle cells

Rodier

Magous

Mochizuki

et al. 1997

Pfl�gers Archiv European Journal of Physiology

View full text Add to dashboard Cite

Glicentin (proglucagon 1-69 GLIC) and oxyntomodulin (proglucagon 33-69 or OXM) are two peptide hormones that are co-released from ileum and large intestine during digestion. They modulate in vivo gastric acid secretion and the gastro-pyloro-duodenal activity. The specificity of their effects is linked to the presence of their C-terminal octapepide. As yet, no isolated target cell that responds specifically to this family of peptides has been described. The present report describes the in vitro effect of human synthetic GLIC, OXM and octapeptide-bearing fragments on smooth muscle cells isolated from the rabbit antrum. GLIC or OXM decreased the mean length of the cells by: 13.9 +/- 0.8% and 15.5 +/- 0.9%, respectively - GLIC being 16 times more potent than OXM (respective EC50 values: 5 and 83 pM). The C-terminal fragments OXM(19-37) and OXM(30-37) were as efficient as GLIC or OXM. Their potencies were OXM = OXM(19-37)>>OXM(30-37). Glucagon, which corresponds to OXM without the C-terminal octapeptide, or glucagon-like peptide-1 (7-36 amide) did not have any effect. The response to OXM was not influenced by antagonists to muscarinic, cholecystokinin or substance P receptors. In conclusion, our studies demonstrate for the first time an isolated target cell that responds specifically to GLIC, OXM and other octapeptide-bearing peptides.

show abstract

A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome

Fujita

Seino

Ishida

et al. 1986

Cancer

View full text Add to dashboard Cite

A 46-year-old man had a 7-year history of severe rash, which was then diagnosed as necrolytic migratory erythema. H e had a weight loss of 6 kg, abnormal glucose tolerance test findings, anemia, glossitis, hair loss, and hypoproteinemia. Plasma amino acids levels were significantly decreased, and the fasting plasma glucagon (IRG) level was high at 5000 to 8000 pg/ml. Circulating IRG significantly increased after oral glucose loading, meal ingestion, and arginine infusion, and decreased with somatostatin infusion and insulin-induced hypoglycemia. No other gut or pancreatic hormone levels in plasma were elevated. Plasma IRG was eluted by gel-filtration, mainly in the position of true glucagon (MW 3500) by antiserum 30K.The rash was markedly improved after infusion of amino acids. Computerized tomography (a) scan and celiac angiography revealed a large pancreatic tumor with multiple liver and lymph node metastases. The pancreatic tumor was totally resected, and was identified as glucagonoma by immunohistochemical technique. Since the plasma IRG levels remained high after surgery, the patient received dimethyltriazenoimidazole carboxamide therapy. After several courses of this treatment, plasma IRG levels decreased to 1000 to 2000 pg/ml, and the hepatic metastases were remarkably diminished in size.Cancer 57: [860][861][862][863][864][865] 1986. LUCAGONOMA is a rare islet A-cell tumor of the pan-G creas. Becker et ul. ' first described this clinical phe-

show abstract

Effect of highly purified porcine gut glucagon-like immunoreactivity (glicentin) on glucose release from isolated rat hepatocytes

Cited by 18 publications

References 18 publications

Insights on glicentin, a promising peptide of the proglucagon family

Insights on glicentin, a promising peptide of the proglucagon family

Effect of glicentin, oxyntomodulin and related peptides on isolated gastric smooth muscle cells

A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome

Contact Info

Product

Resources

About